Royalty Pharma plc
Congressional Trades
No congressional trades in RPRX on record.
Whale Activity
- Increased271
- New109
- Held82
- Decreased215
- Closed44
- No prior filing32
| Filer | Shares | Value | Change |
|---|---|---|---|
| MORGAN STANLEY | 41.1M | $2.40B | decreased |
| Capital International Investors | 33.9M | $1.98B | decreased |
| BlackRock, Inc. | 29.1M | $1.70B | increased |
| FMR LLC | 19.3M | $1.13B | decreased |
| PRICE T ROWE ASSOCIATES INC /MD/ | 14.7M | $858.6M | increased |
| STATE STREET CORP | 13.0M | $755.9M | increased |
| Swedbank AB | 10.3M | $598.8M | decreased |
| BAILLIE GIFFORD & CO | 9.2M | $534.1M | decreased |
| Capital World Investors | 8.8M | $511.0M | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 8.5M | $497.5M | increased |
| Invesco Ltd. | 7.3M | $426.2M | increased |
| VICTORY CAPITAL MANAGEMENT INC | 6.3M | $368.6M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Coyne Terrance P.EVP & CFO | Sale | −9,835 | $68.30 | $672K | Nov 17, 2026 | Form 4 ↗ |
| Coyne Terrance P.EVP & CFO | Sale | −14.8K | $68.30 | $1.0M | Nov 17, 2026 | Form 4 ↗ |
| Hite ChristopherEVP & Chairman, Partnering | Sale | −100.0K | $68.15 | $6.8M | Nov 17, 2026 | Form 4 ↗ |
| Urist MarshallEVP, Research & Investments | Sale | −23.6K | $69.47 | $1.6M | Nov 16, 2026 | Form 4 ↗ |
| Urist MarshallEVP, Research & Investments | Sale | −1,408 | $69.99 | $99K | Nov 16, 2026 | Form 4 ↗ |
| Coyne Terrance P.EVP & CFO | Sale | −90.2K | $68.87 | $6.2M | Nov 16, 2026 | Form 4 ↗ |
| Coyne Terrance P.EVP & CFO | Sale | −7,122 | $68.87 | $490K | Nov 16, 2026 | Form 4 ↗ |
| Coyne Terrance P.EVP & CFO | Sale | −135.2K | $68.87 | $9.3M | Nov 16, 2026 | Form 4 ↗ |
| Urist MarshallEVP, Research & Investments | Sale | −4,126 | $57.10 | $236K | Oct 5, 2026 | Form 4 ↗ |
| Bassler Bonnie LDirector | Grant / award | +642 | $58.41 | $37K | Sep 30, 2026 | Form 4 ↗ |
| Urist MarshallEVP, Research & Investments | Sale | −4,126 | $57.88 | $239K | Sep 28, 2026 | Form 4 ↗ |
| Hite ChristopherEVP & Chairman, Partnering | Sale | −3,927 | $58.93 | $231K | Sep 22, 2026 | Form 4 ↗ |
| Hite ChristopherEVP & Chairman, Partnering | Sale | −96.1K | $58.51 | $5.6M | Sep 22, 2026 | Form 4 ↗ |
| Hite ChristopherEVP & Chairman, Partnering | Gift | −16.8K | $0.00 | $0 | Aug 19, 2026 | Form 4 ↗ |
| Hite ChristopherEVP & Chairman, Partnering | Sale | −100.0K | $59.97 | $6.0M | Aug 18, 2026 | Form 4 ↗ |
| Coyne Terrance P.EVP & CFO | Sale | −1,772 | $59.14 | $105K | Aug 13, 2026 | Form 4 ↗ |
| Coyne Terrance P.EVP & CFO | Sale | −9,230 | $58.59 | $541K | Aug 13, 2026 | Form 4 ↗ |
| Urist MarshallEVP, Research & Investments | Grant / award | +8,252 | $0.00 | $0 | Aug 5, 2026 | Form 4 ↗ |
| Coyne Terrance P.EVP & CFO | Grant / award | +11.0K | $0.00 | $0 | Aug 5, 2026 | Form 4 ↗ |
| Hite ChristopherEVP & Chairman, Partnering | Grant / award | +11.0K | $0.00 | $0 | Aug 5, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 4.5M | $250.7M | 0.26% | Jun 30, 2026 |
| VictoryShares Free Cash Flow ETF Victory Portfolios II | 2.4M | $136.7M | 1.76% | Jun 30, 2026 |
| Invesco Discovery Mid Cap Growth Fund AIM Investment Funds (Invesco Investment Funds) | 1.7M | $99.8M | 1.47% | Jul 31, 2026 |
| VANGUARD HIGH DIVIDEND YIELD INDEX FUND VANGUARD WHITEHALL FUNDS | 1.7M | $97.3M | 0.10% | Jul 31, 2026 |
| iShares Russell 1000 Value ETF iShares Trust | 925.9K | $51.9M | 0.07% | Jun 30, 2026 |
| VANGUARD GLOBAL EQUITY FUND VANGUARD HORIZON FUNDS | 925.0K | $51.9M | 0.68% | Jun 30, 2026 |
| iShares U.S. Pharmaceuticals ETF iShares Trust | 880.1K | $49.3M | 4.33% | Jun 30, 2026 |
| Eventide Dividend Opportunities Fund MUTUAL FUND SERIES TRUST | 774.1K | $43.4M | 3.05% | Jun 30, 2026 |
| iShares MSCI USA Momentum Factor ETF iShares Trust | 653.9K | $38.2M | 0.15% | Jul 31, 2026 |
| Invesco Health Care Fund AIM Investment Funds (Invesco Investment Funds) | 441.0K | $25.8M | 2.13% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list RPRX's shares (CUSIP G7709Q104), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 19.3M shares4.3%
Nov 5, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 19.3M shares4.3%
Nov 5, 2026 · ↗ - Legorreta Investments, LLCSCHEDULE 13D/A · activist (13D) · 37.5M shares7.8%
Aug 17, 2026 · ↗ - Legorreta G. PabloSCHEDULE 13D/A · activist (13D) · 101.8M shares18.7%
Aug 17, 2026 · ↗ - Severgnini Achille G.SCHEDULE 13D/A · activist (13D) · 21.4M shares4.8%
Jun 16, 2026 · ↗ - Butterfield Fiduciary Administrators Trust Company LimitedSCHEDULE 13D/A · activist (13D) · 21.4M shares4.8%
Jun 16, 2026 · ↗ - Capital International InvestorsSCHEDULE 13G/A · passive (13G) · 37.8M shares8.8%
May 14, 2026 · ↗ - Morgan Stanley Investment Management Inc.SCHEDULE 13G/A · passive (13G) · 35.9M shares8.5%
Aug 5, 2025 · ↗ - Morgan StanleySCHEDULE 13G/A · passive (13G) · 38.9M shares9.2%
Aug 5, 2025 · ↗
Corporate Lobbying
No lobbying filings found naming Royalty Pharma plc as the client.
Government Contracts
No federal contract awards found for Royalty Pharma plc.
U.S. Patents
No USPTO patent applications found for Royalty Pharma plc.
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.38B | $2.26B | $2.35B | $2.24B | $2.29B |
| Operating income | $1.56B | $1.29B | $1.49B | $307.1M | $1.43B |
| Net income | $770.9M | $859.0M | $1.13B | $42.8M | $619.7M |
| Diluted EPS | $1.78 | $1.91 | $2.53 | $0.10 | $1.49 |
| Operating cash flow | $2.49B | $2.77B | $2.99B | $2.14B | $2.02B |
| Cash and equivalents | $618.7M | $929.0M | $477.0M | $1.71B | $1.54B |
| Total assets | $19.62B | $18.22B | $16.38B | $16.81B | $17.52B |
| Total liabilities | $9.91B | $7.88B | $6.30B | $7.29B | $7.27B |
As Royalty Pharma plc tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 11, 2026 ↗
Stock Splits
No stock splits in RPRX's price history.
Material Events (8-K)
- 8-K · Items 2.02, 9.01Results of operationsNov 4, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 5, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 4, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.03, 9.01Material agreement · Direct financial obligationMay 28, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 6, 2026
EDGAR ↗ - 8-K · Items 1.01, 5.03, 9.01Material agreement · Bylaw amendmentDec 31, 2024
EDGAR ↗
